MetaCap

Ocugen (OCGN) vs Protalix BioTherapeutics (DE) (PLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Protalix BioTherapeutics (DE) (PLX) has outperformed Ocugen (OCGN) over the past year, gaining 65.7% versus a loss of 33.8%. Over five years, PLX leads with a +192.9% price change compared with -88.1% for OCGN. Ocugen is the larger company by market cap ($260.6 million vs $244.5 million), about 1.1 times the size.

Protalix BioTherapeutics (DE) converts more of its revenue into profit, with a net margin of -12.5% versus -1537.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OCGN-33.80%PLX+65.71%
+121%+37%-47%
Nov 21, 20251 yearNov 20, 2026
OCGN-90.05%PLX+195.92%
+250%+69%-112%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OCGN versus PLX key metrics
MetricOCGNPLX
Share price$0.7679$2.90
Market cap$260.55M$244.52M
1-day change+4.79%-5.23%
YTD return-43.12%+61.11%
1-year return-33.80%+65.71%
5-year return-88.09%+192.93%
P/E ratio (TTM)—12.08
Forward P/E—4.68
EPS (TTM)$-0.20$0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.41M$52.74M
Revenue growth (YoY)+8.83%-1.23%
Net income (latest FY)$-67.85M$-6.60M
Gross margin—48.82%
Operating margin-1425.70%-10.43%
Net margin-1537.41%-12.52%
52-week high$2.73$3.19
52-week low$0.691$1.65
Distance from 52-week high-71.82%-9.09%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1484.84%+313.79%
Average volume7.34M903.48K
Shares outstanding339.31M84.32M
Employees116226
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PLX has outperformed OCGN by 99.5 percentage points over the past year.
  • Protalix BioTherapeutics (DE) is more profitable, keeping -12.5 cents of every revenue dollar as net income versus -1537.4 cents for Ocugen.
  • Ocugen grew revenue faster in its latest fiscal year (+8.83% vs -1.23%).

About Ocugen

OCGN stock →

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees

About Protalix BioTherapeutics (DE)

PLX stock →

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees

OCGN vs PLX FAQ

Which is bigger, Ocugen or Protalix BioTherapeutics (DE)?

Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $244.52M for Protalix BioTherapeutics (DE) (PLX).

Which stock has performed better over the past year, OCGN or PLX?

PLX returned +65.71% over the past 12 months, compared with -33.80% for OCGN (price return, excluding dividends). Past performance does not predict future results.

Are Ocugen and Protalix BioTherapeutics (DE) in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons